论文部分内容阅读
目的观察血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎的临床疗效。方法选取2012年1月—2015年12月在南京市第一医院住院治疗的重症病毒性肺炎患者92例,随机分为对照组和治疗组,每组各46例。对照组患者静脉注射静注人免疫球蛋白(p H 4),10 g/次,1次/d;治疗组在对照组的基础上静脉注射血必净注射液,50 m L/次,2次/d。两组患者均连续治疗7 d。治疗后,比较两组患者临床疗效、临床症状体征改善及高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的水平改变。结果治疗后,对照组和治疗组的总有效率分别为82.61%和91.30%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,治疗组患者退热时间、咳嗽和气喘消退时间明显短于对照组,两组临床症状体征改善情况比较差异有统计学意义(P<0.05)。治疗后,两组患者hs-CRP、IL-6、TNF-α水平均明显降低,同组治疗前后比较具有统计学意义(P<0.05);且治疗组上述炎症因子降低程度更明显,两组比较差异具有统计学意义(P<0.05)。结论血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎临床疗效显著,能有效改善患者的症状体征和炎症因子,具有一定的临床推广应用价值。
Objective To observe the clinical efficacy of Xuebijing injection combined with human immunoglobulin in the treatment of severe viral pneumonia. Methods Ninety-two patients with severe viral pneumonia admitted to the First Hospital of Nanjing from January 2012 to December 2015 were randomly divided into control group and treatment group, with 46 cases in each group. Patients in the control group received intravenous injection of human immunoglobulin (p H 4) intravenously at a dose of 10 g once daily for 24 hours. The patients in the treatment group were given Xuebijing injection at a dose of 50 m L / Times / d. Two groups of patients were treated for 7 days. After treatment, the clinical curative effect, improvement of clinical symptoms and signs and the change of hs-CRP, IL-6 and TNF-α were compared between the two groups. Results After treatment, the total effective rates of the control group and the treatment group were 82.61% and 91.30%, respectively. There was significant difference between the two groups in total effective rate (P <0.05). After treatment, the treatment group patients with fever, cough and asthma subsided time was significantly shorter than the control group, two groups of clinical signs and symptoms were significantly different (P <0.05). After treatment, the levels of hs-CRP, IL-6 and TNF-α in both groups were significantly lower than those in the control group (P <0.05), and the reduction of inflammatory factors was more obvious in the two groups The difference was statistically significant (P <0.05). Conclusion Xuebijing injection combined with human immunoglobulin in the treatment of severe viral pneumonia clinical significant effect, can effectively improve the symptoms and signs and inflammatory factors in patients with a certain clinical application value.